Cargando…
Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort
Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943903/ https://www.ncbi.nlm.nih.gov/pubmed/35356487 http://dx.doi.org/10.1002/dad2.12298 |
_version_ | 1784673611353686016 |
---|---|
author | Gonzales, Mitzi M. Wang, Chen‐Pin Short, Meghan I. Parent, Danielle M. Kautz, Tiffany MacCarthy, Daniel Satizabal, Claudia L. González, David Andrés Royall, Donald R. Zare, Habil O'Bryant, Sid Maestre, Gladys E. Tracy, Russell P. Seshadri, Sudha |
author_facet | Gonzales, Mitzi M. Wang, Chen‐Pin Short, Meghan I. Parent, Danielle M. Kautz, Tiffany MacCarthy, Daniel Satizabal, Claudia L. González, David Andrés Royall, Donald R. Zare, Habil O'Bryant, Sid Maestre, Gladys E. Tracy, Russell P. Seshadri, Sudha |
author_sort | Gonzales, Mitzi M. |
collection | PubMed |
description | Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl‐terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase‐3‐like protein 1 (YKL‐40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204‐2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia‐risk prediction among Mexican American adults. |
format | Online Article Text |
id | pubmed-8943903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89439032022-03-29 Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort Gonzales, Mitzi M. Wang, Chen‐Pin Short, Meghan I. Parent, Danielle M. Kautz, Tiffany MacCarthy, Daniel Satizabal, Claudia L. González, David Andrés Royall, Donald R. Zare, Habil O'Bryant, Sid Maestre, Gladys E. Tracy, Russell P. Seshadri, Sudha Alzheimers Dement (Amst) BlOOD‐BASED BIOMARKERS Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl‐terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase‐3‐like protein 1 (YKL‐40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204‐2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia‐risk prediction among Mexican American adults. John Wiley and Sons Inc. 2022-03-24 /pmc/articles/PMC8943903/ /pubmed/35356487 http://dx.doi.org/10.1002/dad2.12298 Text en © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | BlOOD‐BASED BIOMARKERS Gonzales, Mitzi M. Wang, Chen‐Pin Short, Meghan I. Parent, Danielle M. Kautz, Tiffany MacCarthy, Daniel Satizabal, Claudia L. González, David Andrés Royall, Donald R. Zare, Habil O'Bryant, Sid Maestre, Gladys E. Tracy, Russell P. Seshadri, Sudha Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort |
title | Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort |
title_full | Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort |
title_fullStr | Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort |
title_full_unstemmed | Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort |
title_short | Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort |
title_sort | blood biomarkers for cognitive decline and clinical progression in a mexican american cohort |
topic | BlOOD‐BASED BIOMARKERS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943903/ https://www.ncbi.nlm.nih.gov/pubmed/35356487 http://dx.doi.org/10.1002/dad2.12298 |
work_keys_str_mv | AT gonzalesmitzim bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT wangchenpin bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT shortmeghani bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT parentdaniellem bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT kautztiffany bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT maccarthydaniel bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT satizabalclaudial bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT gonzalezdavidandres bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT royalldonaldr bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT zarehabil bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT obryantsid bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT maestregladyse bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT tracyrussellp bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort AT seshadrisudha bloodbiomarkersforcognitivedeclineandclinicalprogressioninamexicanamericancohort |